安乃定 | 53908-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 安乃定
• 英文名称: 2-(Acetyloxy)benzoic acid mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
• 英文别名: 2-acetyloxybenzoic acid;1,3,7-trimethylpurine-2,6-dione
• CAS: 53908-20-6
• 化学式: C17H18N4O6
• 分子量: 374.3
• InChiKey: AEDBPCUEFFFHBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.28
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO
  申请人：Allergan Sales, LLC

  公开号：EP3956025A1

  公开（公告）日：2022-02-23
• [EN] APPARATUS AND METHOD FOR THE ASSESSMENT OF CONCENTRATION PROFILING AND PERMEABILITY RATES<br/>[FR] APPAREIL ET PROCÉDÉ PERMETTANT L'ÉVALUATION D'UN PROFILAGE DE LA CONCENTRATION ET DES TAUX DE PERMÉABILITÉ
  申请人：PION INC

  公开号：WO2016168445A1

  公开（公告）日：2016-10-20

  An apparatus (10) for the combined assessment of dissolution and permeability relies on a receiver chamber (14) that is contained within a donor chamber (12). A membrane (16) is provided between the two chambers. Measurements can be taken to determine solute amounts of a drug introduced in the donor chamber and amounts of permeated solute in the receiver chamber. Also described are techniques for the assessment of a dissolution rate and total amount of dissolved compound, together with their effect oil absorption potential of a compound or a compound product as well as approaches for evaluating in vivo relevant differences between formulations of a compound through their effect on the absorption potential of the compound.
• [EN] CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO<br/>[FR] ANTAGONISTES DU CGRP POUR LE TRAITEMENT DE MAUX DE TÊTE LIÉS À UN ABUS DE MÉDICAMENTS, DE MAUX DE TÊTE POST-TRAUMATIQUES, DE SYNDROME POST-COMMOTION ET DE VERTIGE
  申请人：ALLERGAN SALES LLC

  公开号：WO2020214906A1

  公开（公告）日：2020-10-22

  The application provides methods for treating, preventing, alleviating or reducing the frequency of occurrence of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo in patients by the administration of calcitonin gene-related peptide (CGRP-antagonists). The CGRP-antagonists can be selected from ubrogepant or atogepant, or a pharmaceutically acceptable salt, ester or prodrug thereof. Anti-CGRP antibodies, such galcanezumab, fremanezumab, eptinezumab, and erenumab can also be used.